A Look into Radiofrequency Ablation Devices Industry……Deep Analysis…..
The global radiofrequency
ablation devices market size is
anticipated to reach USD 6.7 billion by
2026, according to a new report by Grand View Research, Inc. It is expected
to register a CAGR of 11.6% during the forecast period. Increasing preference
for minimally invasive surgeries, growing geriatric population, and rise in
healthcare spending for better disease treatment are expected to propel the
growth.
With Covid-19 infections rising globally, the
apprehension regarding a shortage of essential life-saving devices and other
essential medical supplies in order to prevent the spread of this pandemic and
provide optimum care to the infected also widens. In addition, till a
pharmacological treatment is developed, ventilators act as a vital treatment
preference for the COVID-19 patients, who may require critical care. Moreover,
there is an urgent need for a rapid acceleration in the manufacturing process
for a wide range of test-kits (antibody tests, self-administered, and others).
The report will account for Covid19 as a key market contributor.
According to the American Society of
Plastic Surgeons, by the end of 2015, 15.9 million minimally invasive cosmetic
surgeries were performed in U.S. According to the Centers for Disease Control
and Prevention (CDC), more than six million laparoscopic procedures are
performed across the U.S. and EU countries every year.
Radiofrequency ablation is now used
early in the management of patients suffering from atrial tachycardia or atrial
fibrillation or other kinds of coronary disease. This factor is anticipated to
boost the market growth. According to the American College of Cardiology
Foundation, coronary heart disease is the leading cause of deaths (43.8%) in
U.S., followed by stroke (16.8%), heart failure (9.0%), high BP (9.4%), and
other CVDs (17.9%). By 2035, the total cost of CVD is expected to reach USD 1.1
trillion and is projected to affect 45.1% (130 million) adults in U.S.
Radiofrequency ablation can also be
used to reduce neck pain, low-back pain, arthritis, and pelvic and peripheral
nerve pain. According to WebMD LLC., RFA has been proven to be effective in
more than 70% of the patients experiencing pain. Pain relief from RFA can last
from six to 12 months or even a year.
To Request Sample Copy of this report, click the link:
The global radiofrequency ablation devices market size was
valued at USD 2.8 billion in 2018 and is projected to expand with CAGR of 11.6%
over the forecast period. The market is majorly driven by growing prevalence of
chronic and cardiovascular diseases and preference for minimally invasive
surgeries. According to the Centers for Disease Control and Prevention (CDC),
Atrial Fibrillation (AF) is projected to affect 17.9 million in Europe by 2060
and 12 million people in the U.S. respectively by 2050.
In addition, growing geriatric population coupled with rising
life expectancy is expected to boost the growth. Geriatric people are more
susceptible to chronic diseases, driving the demand for highly effective
treatment, which in turn boosts the RF ablation market. According to the World
Health Organization (WHO), the world’s population aged 60 years and above is
expected to reach 2 billion by 2050 from 900 million in 2015. The demographic
tends to have the highest disability rate and maximum need for effective care
and treatment, which is anticipated to propel the growth.
Further key findings from the report suggest:
·
Disposable equipment held the largest
market share in 2018 due to reduced morbidity and mortality and the ability of
the equipment to provide treatment in an outpatient setting. For example,
Radiopaque RF cannula (Halyard Worldwide, Inc) provides improved visualization
under fluoroscopy for accurate positioning, resulting in a targeted treatment
·
Cardiology and cardiac rhythm management is
anticipated to be the fastest-growing segment during the forecast period due to
disease prevalence, growing awareness, and adoption of minimally invasive
operations. In 2012 RFA-Academia launched an initiative to increase awareness
in Europe and to teach endoscopists safe and justified application of RFA to
reduce the disease burden
·
North America is anticipated to continue leading
the radiofrequency ablation devices market during the forecast period due to
high healthcare expenditure, incidence of cardiac disease and cancer, and the
number of patients suffering from pain
·
Asia Pacific is expected to witness
significant growth over the next decade due to increasing demand for minimally
invasive procedures to treat cancer and growing awareness regarding the
benefits of ablation method over the conventional surgical procedures
·
Some of the key players are Boston
Scientific Corporation; Medtronic; Stryker; Cosman Medical, Inc.; St. Jude
Medical; Smith & Nephew; Johnson & Johnson (J&J) Services, LLC; and
AngioDynamics.
Growing
healthcare expenditure and preference for minimally invasive surgeries has
become a major factor driving the market growth. Radiofrequency ablation is an
effective treatment for small cancers and can be repeated if new cancer
appears. According to the U.S. Census Bureau, the global healthcare spending is
anticipated to reach USD 18.28 trillion by 2040, at a CAGR of 2.6%. This is
anticipated to positively influence the revenue generation from radiofrequency
ablation devices.
Rising
prevalence of chronic pain disorders such as arthritis and osteoporosis coupled
with improving healthcare infrastructure will propel market growth. According
to the U.S. Department of Health & Human Services, in 2015, 15 million
adults were suffering from severe joint pain due to arthritis and by 2040 an
estimated 78 million (26%) U.S. adults aged 18 years and above are anticipated
to be diagnosed with arthritis.
Based
on product, the market is trifurcated into disposable, capital, and reusable
equipment. Disposable equipment accounted for the largest market share in 2018
and is expected to witness the fastest CAGR over the forecast period. Advanced
technology with the capability of creating large regions of coagulative
necrosis in a controlled manner, being relatively low toxic and decreased the
risk of complication drive growth of the disposable radiofrequency ablation
devices market.
Product
launches will drive the market growth over the forecast period. In April 2017,
Medtronic launched OsteoCool RF Ablation system in Canada for the indication of
bone metastases. This is the only RF ablation system with dual probe
capabilities that provides customized, flexible, and predictable treatment.
Browse Press
Release of this report:
Grand View Research has segmented the
global radiofrequency ablation devices market based on type:
Radiofrequency Ablation Devices Product Outlook (Revenue,
USD Million, 2015 - 2026)
·
Disposable Equipment
·
Capital Equipment
·
Reusable Equipment
Radiofrequency Ablation Devices Mode of Delivery Outlook
(Revenue, USD Million, 2015 - 2026)
·
Surgical Oncology
·
Cardiology & Cardiac Rhythm
Management
·
Cosmetology
·
Gynecology
·
Pain Management
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Comments
Post a Comment